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A B S T R A C T
Even though mutations in the tumor suppressor, BRCA1, markedly increase the risk of breast and ovarian
cancer, most breast and ovarian cancers express wild type BRCA1. An important question is therefore
how the tumor-suppressive function of normal BRCA1 is overcome during development of most cancers.
Because prolactin promotes these and other cancers, we investigated the hypothesis that prolactin in-
terferes with the ability of BRCA1 to inhibit the cell cycle. Examining six different cancer cell lines with
wild type BRCA1, and making use of both prolactin and the growth-inhibiting selective prolactin recep-
tor modulator, S179D PRL, we demonstrate that prolactin activation of Stat5 results in the formation of
a complex between phospho-Stat5 and BRCA1. Formation of this complex does not interfere with nuclear
translocation or binding of BRCA1 to the p21 promoter, but does interfere with the ability of BRCA1 to
transactivate the p21 promoter. Overexpression of a dominant-negative Stat5 in prolactin-stimulated cells
resulted in increased p21 expression. We conclude that prolactin inhibits a major tumor-suppressive func-
tion of BRCA1 by interfering with BRCA1’s upregulation of expression of the cell cycle inhibitor, p21.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Mutations in Breast Cancer 1, BRCA1, have been implicated in
the development of multiple cancers, including those of the breast,
ovary and prostate [1–4]. People with BRCA1mutations have amuch
higher incidence of tumor development [5], and BRCA1 knockout
in mouse models causes tumor formation [6]. BRCA1 has several
different tumor-suppressive functions, including DNA damage repair,
transcriptional regulation, and ubiquitination [7]. For this study, our
focus was on the ability of BRCA1 to transactivate the cyclin de-
pendent kinase inhibitor, CDKN1A (p21). Increased expression of
p21 results in G1/S phase arrest and may eventually lead to apop-
tosis [8]. Given the clinical importance of BRCA1 as a tumor
suppressor (5), it is surprising that most tumors have wild type
BRCA1: in a recent study examining 41 human breast cancer cell
lines, over 90% exhibited wild type BRCA1 [9], and similar results
were reported in ovarian tumors [10,11]. Because the level of ex-
pression of BRCA1 can be illustrative of chemoresistance through
DNA damage repair [12], it seems that the entire function of wild
type BRCA1 is not lost during the formation of many tumors. How
there can be elevated BRCA1 with an intact DNA repair function,
but a lost or overwhelmed anti-proliferative function, remains
unclear.
Prolactin is a peptide hormone best known for its ability to
promote milk production [13]. It is also an important growth factor
for most tissues, and many cancer cells produce prolactin as an
autocrine growth factor [14]. When binding to its receptor, prolac-
tin signals through multiple pathways, including the Jak2/Stat5
pathway, resulting in both proliferation and differentiation. Acti-
vated Stat5 has been reported to be associated with tumor
progression in some, but not all studies (reviewed in [15]). In breast
cancers, constitutively-activated and nuclear-localized Stat5 was
found in 76% of invasive breast adenocarcinomas [16]. In prostate
cancers, hyper-activated Stat5 was associated with higher histo-
logical grade [17]. Thus, regulation of prolactin–Stat5 signaling may
be crucial in cancer transformation.
BRCA1 is expressed in high amounts in proliferating cells, pre-
sumably to ensure repair of any damaged DNA [18]. However, under
other circumstances, induction of BRCA1 leads to upregulation of
p21 and inhibition of the cell cycle [8]. In the mammary gland, as
demonstrated by work from the Chodosh laboratory, the expres-
sion of BRCA1 is increased under circumstances when prolactin is
proliferative, and decreased when prolactin is more differentiative
[19]. A change in the role of prolactin from a hormone that pro-
motes proliferation to one that promotes differentiation can be
achieved through interaction with different receptor isoforms or by
post-translational modiﬁcation of prolactin: Thus, we and others
have produced direct and associative evidence that higher expression
Abbreviations: PRL, prolactin; LFPRLR, long form prolactin receptor; SF1bPRLR,
short from 1b prolactin receptor; S179DPRL, a selective prolactin receptor modulator.
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levels of long form prolactin receptor (LFPRLR) promote prolifera-
tion and disease progression, while more short form 1b prolactin
receptor (SF1b PRLR) expression reduces proliferation and favors
differentiation in mammary [20–23] and other [24,25] tumor cells.
In addition, unmodiﬁed prolactin stimulates cell growth while a
mimic of phosphorylated prolactin, the selective PRLR modulator
S179DPRL, inhibits cell growth and promotes differentiation both
in vitro and in vivo [25–29]. Thus, we initially hypothesized that
the two forms of the PRLR and prolactin and S179D PRL would have
opposite effects on the expression and function of BRCA1, an hy-
pothesis that was proven incorrect. Instead, we demonstrate that
prolactin activation of Stat5 results in the formation of a complex
between phospho-Stat5 and BRCA1 that inhibits the function of
BRCA1 at the p21 promoter.
Materials and methods
Cell culture and treatment
All cell lines were originally purchased from ATCC and were authenticated uti-
lizing Short Tandem Repeat (STR) analysis. Cells were routinely cultured in RPMI
1640 medium supplemented with 10% FBS and were used for experiments with
passage number <20. Six human cancer cell lines were chosen and their cancer type
and BRCA1 and p53 status are listed in Table 1. 5 × 105 cells were treated with pro-
lactin or S179DPRL at 100 ng/mL for 24, 48 and 72 hours and the expression of BRCA1
was determined. Most experiments used non-transfected cells, but transfection was
required for the promoter analysis, and to assess the result of increased expression
of LFPRLR or SF1b PRLR.
Plasmid construction
The full length (2400 bp) p21 promoter construct was a gift from L.P. Freed-
man [30]. The different lengths of the p21 promoter region were ampliﬁed by PCR,
ligated to TA vector, digested with restriction enzymes and cloned into pGL4.17 vector
(Promega, cat #E6721). Primer information is included in Table 2. The 1390 bp p21
promoter construct was digested from the 1439 bp p21 promoter construct using
DraI digestion and then self-ligated to form the 1390 bp p21 promoter construct.
This construct was missing the fragment from −84 to −126 (cut by DraI) where the
BRCA1-interacting element was present. The 1224 bp plasmid was constructed by
generating a XhoI cutting site at 1227 bp through PCR mutagenesis and then di-
gesting with XhoI to remove the fragment between 2400 bp and 1224 bp.
The Stat5a 740 bp truncation construct was characterized by Yamashita et al.
and Wang et al. [31,32] and was shown to act as a dominant negative of Stat5a. The
amino acids after 740 were deleted from Stat5a.
Immunoprecipitation
Cells were incubated in serum free RPMI1640 for 24 hours to synchronize the
cells and lower background signals and then treated with 100 ng/mL PRL or S179DPRL
for 24 hours and harvested using 100 μL RIPA lysis buffer. The protein concentra-
tion was quantiﬁed using Bio-Rad protein assay (Bio-Rad, cat# 500-0006). Protein
lysates (200 μg) were ﬁrst precleared with 5 μL normal rabbit IgG and then immu-
noprecipitated with 5 μL rabbit polyclonal BRCA1 antibody (Santa Cruz sc-646) and
precipitated with 100 μL protein A/G beads (Pierce #20421). The beads were then
washed 5 times with IP buffer (25 mM Tris, 150 mM NaCl, pH 7.2) and eluted with
50 μL Elution buffer (0.1 M Glycine–HCl, pH 2.5). The eluate was adjusted to phys-
iological pH by adding 10 μL Neutralization buffer (1 M Tris, pH 9) per 100 μL eluate.
The eluate was analyzed by Western blot.
Nuclear and cytoplasmic extraction
One milliliter of cytoplasmic extraction buffer (1 M Hepes, 3 M KCl, 0.25 M
EDTA, 10% NP40) was added, and the cells were scraped and transferred to a
1.5 mL microcentrifuge tube. After centrifugation for 1 min at 14,000 rpm at 4 °C,
the supernatant (cytoplasmic fraction) was collected. The pellet was resuspended
in 100 μL ice cold cytoplasmic extraction buffer, mixed by pipetting up and down
and incubated on ice for 10 min before centrifugation for 10 min at 13,000 g at
4 °C. Nuclear extraction buffer (1 M Hepes, 3 M NaCl, 0.25 M EDTA) of 80 μL was
then added to the pellet and the pellet was resuspended. This suspension was
shaken for 10 min at 4 °C, and then centrifuged for 10 min at 13,000 g at 4 °C. The
pellet was separated from the supernatant (Nuclear fraction). Both cytosolic and
nuclear fractions were subjected to Western blot or immunoprecipitation
analysis.
Chromatin immunoprecipitation
Cells were seeded in 10 cm dishes and cultured at 37 °C until 80% conﬂuent.
Medium was changed to serum-free and cells were incubated for 24 hours before
prolactin treatment. Then, 100 ng/mL of prolactin or S179DPRL was added for 20
hours. Cells were then washed with 10 mL Dulbecco’s PBS (twice) and ﬁxed by
adding 10 mL DPBS containing 270 μL 37% formaldehyde for 10 min at room tem-
perature. Cross-linking was stopped by adding 1 mL 1.25 M glycine for 5 min at
25 °C. Cells were washed and the pellet was resuspended in 1 mL CHIP sonication
buffer plus protease inhibitors (1% Triton X-100, 0.1% Deoxycholate, 50 mM Tris
8.1, 150 mM NaCl, 5 mM EDTA). Samples were sonicated, centrifuged at 13,000 g
for 15min at 4 °C to remove debris, and the supernatant was retained and precleared
using 1–5 μg IgG plus 40 μL protein A/G beads for 30–60 min. ChIP buffer (10%
Triton X-100, 1.9% EDTA, disodium dehydrate, 1% SDS) was added to a ﬁnal volume
of 1 mL for each sample. To this was added 10 μl BSA (10 μg/μl) with thorough
mixing. Each sample was divided into Input, anti-BRCA1 and anti-rabbit IgG. ChIP
buffer without Triton (800 μL) and 5 μg antibody (BRCA1/rabbit IgG) were added
to tubes and nutated at 4 °C for 2 hours. Protein A/G beads were washed before
use and then 40 μL was added to each tube along with 2 μL herring sperm DNA
(10 mg/mL) to avoid nonspeciﬁc DNA binding and nutated at 4 °C for 2 h. Samples
were centrifuged at 400 g for 2.5 min at 4 °C and the supernatants stored at −20 °C.
Beads were washed with 1 mL cold ChIP buffer without protease inhibitors by
inverting the sample to suspend the resin then pelleting again, as before, with
removal of supernatants. Following two further washes, the pelleted and drained
beads were resuspended in 250 μL of Elution buffer (1 mL 10% SDS, 2 mL 0.5 M
NaHCO3, 10 μL sperm DNA) and placed on a nutator at 25 °C for 15–20 min. To
each were added 40 μl 2.5 M NaCl followed by placement in a 65 °C bath for 4 h.
The precipitated DNA fragment was puriﬁed using gel extraction (Sigma Genelute
Gel extraction NA1111-1KT). The eluate was then used for PCR.
Western blot
Depending on the size of target protein, SDS-PAGE gels were either high per-
centage (12%) to analyze small proteins such as p21 or low percentage (7%) to detect
large proteins such as BRCA1. Gels were run at 100 V (constant) and transferred onto
nitrocellulose paper using a standard semi-dry method. Blots were then blocked with
5% BSA at 25 °C for one hour and incubated with 1st antibodies overnight at 4 °C.
Blots were then washed and incubated with HRP-linked 2nd antibody against species
of 1st antibody for 1 hour at 25 °C and then developed. Antibodies used in this study
are listed in Table 3.
Cell cycle analysis
TOV-112D and T47D cells were synchronized in serum-deprived medium for 24
hours followed by treatment with DPBS or 100 ng/mL prolactin or S179DPRL for
another 24 hours. Cells were collected and stainedwith propidium iodide (eBioscience
00–6990) following the manufacturer’s instructions. Cell cycle was analyzed by ﬂow
cytometry using FlowJo software.
Table 1
Cell lines and status of BRCA1 and p53. Wt, wildtype; NHS, no hotspot mutations.
Cell line Tissue type ATCC number Some characteristics
T-47D Breast cancer HTB-133 p53 mutant, BRCA1 wt
MCF-7 Breast cancer HTB-22 Both p53 and BRCA1 wt
PC3 Prostate cancer CRL-1435 p53 null, BRCA1 wt
TOV-112D Ovarian cancer CRL-11731 p53 mutant, BRCA1 NHS
OV-90 Ovarian cancer CRL-11732 p53 mutant, BRCA1 NHS
TOV-21G Ovarian cancer CRL-11730 p53 wt, BRCA1 NHS
Table 2
Primers used for cloning.
2400 bp A gift from Freedman L.P. [30].
1439 bp F: AGGAGAAAGAAGCCTGTCCT
R: GCAGCTGCTCACACCTCAGC
1224 bp F: GTTTCAGGCACAGACTCGAGGCAAAGGTGAAGTCCAGG
R:CCTGGACTTCACCTTTGCCTCGAGTCTGTGCCTGAAAC
840 bp F: TCCTGGCCAACAAAGCTGCT
R: GCAGCTGCTCACACCTCAGC
143 bp F: CGCTGGGCTAGCCAGG
R: CCCAAGCTTAGCTGCTCACACCTCAGC
Stat5a 740 bp Forward: GGGGATCCATGGCGGGCTGGATCCAG
Reverse: CCGCTCGAGTCACTGTGGGTACATGT
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Statistical analyses
All experiments were conducted a minimum of 3 times using a minimum of trip-
licates on each occasion. All cell lines were used for all analyses, with the exception
of the receptor transfection experiments that were conﬁned to the low endog-
enous receptor expressing cell line, PC3. Statistical signiﬁcance was determined by
ANOVA with post tests and Bonferroni corrections for multiple comparisons, where
applicable. A p value < 0.05 was considered signiﬁcant.
Results
BRCA1 levels were increased by both prolactin and S179DPRL
Since prolactin promotes proliferation and S179D PRL inhibits
proliferation and promotes differentiation [25–29,33], and there was
some indication in the literature that BRCA1 increases during pro-
liferation and decreases during differentiation [19], we hypothesized
that prolactin and S179D PRL would have opposite effects on BRCA1
levels. Contrary to expectations, BRCA1 levels were increased in re-
sponse to both prolactin and S179DPRL. This occurred in all six cancer
cell lines tested, although the degree and the peak time of induc-
tion varied in different cell types. Fig. 1 shows examples of breast
Table 3
Antibodies used.
Name Supplier and cat. # Dilution used
p21 Santa Cruz
sc-397
1:1,000 in 5% BSA with
0.02% sodium azide
BRCA1 Santa Cruz
sc-646
1:200 in 5% BSA with 0.02%
sodium azide
Stat5a Santa Cruz
sc-1081
1:1,000 in 5% BSA with
0.02% sodium azide
pStat5a Santa Cruz
sc-101806
1:1,000 in 5% BSA with
0.02% sodium azide
p-ERK Santa Cruz
sc-7383
1:1,000 in 5% BSA with
0.02% sodium azide
ERK 1/2 Santa Cruz
sc-94
1:1,000 in 5% BSA with
0.02% sodium azide
pAkt Cell Signaling
#4060X
1:1,000 in 5% BSA with
0.02% sodium azide
Akt Santa Cruz
sc-5298
1:1,000 in 5% BSA with
0.02% sodium azide
Actin Santa Cruz
sc-1016
1:10,000 in 5% BSA with
0.02% sodium azide
Goat anti-rabbit HRP Sigma A0545 1:40,000 in 10 mL TBST buffer
Goat anti-mouse HRP Santa Cruz sc-2062 1:10,000 in 10 mL TBST buffer
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Fig. 1. Both prolactin and S179DPRL elevate BRCA1. (A, B) Western blots and quantiﬁcation of same demonstrating an elevation in BRCA1 in response to both prolactin and
S179DPRL in T47D (A) and TOV-112D (B) cells. Cells were seeded in 6 well plates and treated with 100 ng/mL prolactin or S179DPRL for 48 hours. Values were normalized
to β-actin. *p < 0.05. (C) Western blots showing the time course of induction of BRCA1. Cells were seeded in 6 well plates and treated with 100 ng/mL prolactin or S179DPRL
for 24, 48, 72 hours. Vehicle control cells shown were from the 0 hour time point. Controls were assayed at 0, 24, 48, 72 hour time point and there was no difference in
BRCA1 expression.
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(MCF7, T-47D) and ovarian (OV90, TOV-112D, and TOV-21G) cancer
cell lines and the quantiﬁcation of the response in T-47D and
TOV112D cells and Fig. 2 shows the response in prostate cancer (PC3)
cells.
Since different spliced PRLR isoforms mediate signaling to pro-
liferation or inhibition of proliferation and promotion of
differentiation [20–25], we then asked whether the different time
courses and degrees of BRCA1 induction in the different cell lines
were the result of differential PRLR isoform expression. The PC3 cell
line was chosen for PRLR isoform transfection experiments because
the low levels of endogenous expression of PRLRs allowed for trans-
fection of the receptors without excessive overexpression. Even
though endogenous receptor expression is low, the receptors in PC3
cells have nevertheless been shown to respond to prolactin by ac-
tivating downstream signaling pathways [34]. Fig. 2 not only
quantiﬁes the PC3 response, but also shows that increased expres-
sion of the proliferative (LFPRLR) or the anti-proliferative (SF1b PRLR)
isoform of the receptor led to an increase in BRCA1 levels in re-
sponse to either prolactin or S179DPRL. Thus, even though the short
receptor (SF1b PRLR) lacks a large portion of the intracellular sig-
naling domain, it couldmediate the ability of both ligands to increase
BRCA1 levels. Furthermore, because there was no difference in the
result between the two forms of receptor, differential ratios of LFPRLR
to SF1b PRLR expression would not explain the differential time
course or degree of response among the cell lines.
BRCA1 induction by prolactin and S179DPRL in terms of p21
elevation
To evaluate the impact of prolactin and S179DPRL on the down-
stream function of BRCA1, expression of the cell cycle inhibitor, p21,
was examined. Consistent with the anti-proliferative role of
S179DPRL, BRCA1 induced by S179DPRL was able to increase p21
protein. Also, in agreement with the proliferative function of pro-
lactin, BRCA1 induced by prolactin was not capable of increasing
p21. Fig. 3 shows examples from a breast, ovarian and prostate cancer
cell line, and panel C shows that the result was unchanged in PC3
prostate cancer cells overexpressing either LFPRLR or SF1b PRLR.
To be sure that receptor transfection did not distort the results, in-
duction of p21 protein was also examined in non-transfected cells.
As shown in Fig. 4, induction of p21 in response to S179DPRL was
dose-related in TOV-112D and PC3 cells, but seemed not to reach
amaximum in T47D cells, perhaps as a result of expression of a larger
number of PRLRs. By contrast, there was no effect of prolactin at
any dose in the breast, ovarian and prostate cancer cell lines.
Induction of p21 is also reﬂected in the effect on the cell cycle.
With S179DPRL-treated TOV-112D, there were no cells in S phase
and the percentage of cells in G1 was higher than control or
prolactin-treated. Also, 12.5% of cells were undergoing apoptosis after
exposure to S179DPRL. In the more slowly-growing T47D cells, the
effects after 24 hours of treatment were more subtle, but included
an increase in G1, as appropriate to the action of p21 (Fig. 5).
Expression of p21 is regulated by a variety of factors and the pro-
moter region has many potential binding sites for transcription
factors, including BRCA1 (Fig. 6A). To determine which transcrip-
tion factors were involved in the induction of p21, we made a series
of constructs containing different regions of the p21 promoter up-
stream of luciferase, ranging from the full length promoter to 143 bp
(Fig. 6A). To eliminate the confounding inﬂuence of p53, PC3 cells,
which have null p53, were chosen to conduct the promoter anal-
ysis. PC3 cells transfectedwith different constructs and the SF1b PRLR
were then analyzed after treatment with prolactin or S179DPRL for
20 hours.
With the full length p21 promoter or other constructs contain-
ing the BRCA1 response element (93–133 bp on the p21 promoter)
[8], an S179DPRL stimulus increased luciferase expression. In ad-
dition, as one would expect in this cell line, removal of both p53
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Fig. 2. The isoform of the PRLR is irrelevant to the response. Quantiﬁcation of Western
blot after PC3 cells were transfected with either LFPRLR or SF1b PRLR and treated
with 100 ng/mL prolactin or S179DPRL for 72 hours. Values normalize to β-actin
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Fig. 3. S179DPRL, but not prolactin, increased p21 expression even though both el-
evated BRCA1. Cells were seeded in 6well plates and treated with 100 ng/mL prolactin
or S179DPRL for 72 hours. p21 expression was then analyzed by Western blot and
normalized to β-actin in T47D cells (A), Tov-112D cells (B) and PC3 cells overexpressing
either LFPRLR or SF1bPRLR (C) (**p < 0.01; *p < 0.05).
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elements had no effect (1439 bp, 1224 bp and 840 bp constructs).
Most interestingly, the minimal promoter (143 bp) containing only
the BRCA1 response element and a basic TATA box was still able to
drive luciferase expression in response to S179DPRL. On the other
hand, when the BRCA1 response element was removed while
keeping all others intact (1390 bp), the expression of luciferase went
down to unstimulated levels, thereby unequivocally indicating BRCA1
involvement in p21 induction in response to S179DPRL (Fig. 6B). In
comparison with the results with S179DPRL, the prolactin-induced
BRCA1 did not increase luciferase activity in cells transfected with
the same constructs (data not shown); the luciferase values were
the same as with no addition of prolactin. This implied functional
interference with BRCA1 when cells were stimulated with prolactin.
The activated signaling molecule, p-Stat5, formed a complex with
BRCA1 and interfered with its p21 transactivation function
In questioning how S179DPRL increased levels of BRCA1 and p21,
and yet prolactin, while increasing levels of BRCA1, had no effect
on p21 expression, we considered the differences in signaling
between the two ligands. Among the 5 signaling molecules exam-
ined (Erk, Stat5, Akt, AMPK and PKC), activation of Stat5 was
completely different with prolactin versus S179DPRL in all cell lines.
Consistent with previous results, prolactin activated Stat5 whereas
S179DPRL did not (Fig. 7, showing examples of T47D and PC3 cells
with endogenous high and low expression of PRLRs, respectively).
A mechanism through which activation of Stat5 might inter-
fere with BRCA1 would be for activated Stat5 and BRCA1 to form a
complex. To test whether there was an interaction between acti-
vated Stat5 and BRCA1, co-immunoprecipitation was performed
using a BRCA1 antibody and Western blotting with anti-p-Stat5.
Fig. 8A shows the result with the human breast cancer cell line,
T-47D. This cell line (as all other cell lines used in this study) ex-
presses autocrine prolactin. As seen in Fig. 8A, both prolactin
treatment (cells exposed to both exogenous and autocrine) and
control (cells exposed to autocrine) showed complex formation
between p-Stat5 and BRCA1. This did not occur with S179DPRL treat-
ment. Thus, S179DPRL not only did not activate Stat5, but also
inhibited the ability of autocrine prolactin to activate Stat5.
There are three possible ways formation of a complex between
p-Stat5 and BRCA1 might interfere with the ability of BRCA1 to in-
crease p21 expression: (1) complex formation might prevent entry
of BRCA1 into the nucleus, (2) complex formation might prevent
binding of BRCA1 to the p21 promoter, or (3) once in the nucleus
and bound to the promoter, complex formation might prevent
transactivation of the promoter. To determine which of these was
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Fig. 4. The response to S179DPRL is dose-related. (A) T47D, (B) TOV-112D and (C) non-transfected PC3 cells were treated for 48 hours, and subjected to quantitative Western
blot analysis normalized to β-actin (*p < 0.05).
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the case, cells were treated with prolactin and the cytosolic and
nuclear fractions were isolated and subjected to immunoprecipi-
tation with anti-BRCA1, followed by immunoblotting with anti-p-
Stat5. As shown in Fig. 8B, the BRCA1–p-Stat5 complex was located
in the nucleus, indicating no effect on entry into the nucleus. To
examine the interaction of BRCA1 with the p21 promoter after pro-
lactin and S179DPRL treatment, whole cell chromatinwas crosslinked
and immunoprecipitated with anti-BRCA1 antibody and the inter-
action of BRCA1with the p21 promoter was examined (Fig. 8C). There
was no difference between prolactin or S179DPRL treatment of cells
in the binding of BRCA1 to the p21 promoter. This left us with the
possibility that p-Stat5–BRCA1 complex formation interfered with
the transcription of p21. To determine whether this was the case,
we constructed the dominant negative form of Stat5a described by
Yamashita et al. andWang et al. [31,32]. With overexpression of this
dominant negative, non-phosphorylatable form of Stat5a, treat-
ment with prolactin was now able to drive p21 expression. Thus,
prolactin’s activation of Stat5 interferes with BRCA1’s p21
transactivation function (Fig. 8D). To determine whether this in-
terference was speciﬁc for prolactin or common to several activators
of Stat5, two additional activators of Stat5, human IL-2 and human
growth hormone, were tested for their ability to both induce BRCA1
expression and activate the minimal p21 promoter. While treat-
ment with growth hormone or IL-2 increased expression of BRCA1
(Fig. 8E), there was no induction of luciferase driven by the minimal
p21 promoter (Fig. 8F and G). Furthermore, growth hormone an-
tagonized the effect of S179DPRL (Fig. 8F).
Discussion
Contrary to our initial hypothesis, we found the form of the PRLR
associated with proliferation as well as the form associated with
inhibition of proliferation tomediate increased levels of BRCA1. Thus,
we can conclude that it is not differential ratios of these two forms
of the receptor that regulate the level of BRCA1 or responsiveness
to ligand. Rather, the responsiveness to ligand in terms of in-
creased BRCA1 seems related to overall expression levels of all PRLRs.
For example, non-transfected PC3 cells with low levels of PRLR re-
sponded the least well and T47D cells with high levels of PRLR
responded most robustly. The LFPRLR and SF1b PRLR have very dif-
ferent intracellular signaling domains [22]. Because both forms of
the receptor transduced the signal leading to increased levels of
BRCA1, we know that the signaling pathway is common to both re-
ceptor isoforms, and from the work of Nelson et al. this is most likely
via Akt [35].
Again contrary to our initial hypothesis, both prolactin and
S179DPRL induced BRCA1 expression. Thus, whether we exam-
ined receptors or ligands with opposite effects on proliferation, both
versions of each increased BRCA1 levels. It therefore does not appear
that the overall level of BRCA1 in a cell dictates whether or not cell
proliferation occurs.
Even though both ligands elevated levels of BRCA1, only with
S179D PRL did increased levels of BRCA1 lead to an increase in the
downstream cell cycle-regulating molecule, p21. Since p21 is down-
stream of either p53 or BRCA1 [36], use of a cell line with non-
functional p53 for the promoter analysis demonstrated that p53 was
not required for S179DPRL-mediated p21 induction. This was further
demonstrated by the lack of effect of removal of p53 response el-
ements from the promoter. By contrast, absolute dependence on the
BRCA1 response element was demonstrated by equivalent re-
sponses by the full length and 143 bp minimal promoter and the
lack of activity of the full length promoter minus the BRCA1 re-
sponse element. These results emphasize the importance of direct
interaction of BRCA1 with the p21 promoter.
A previous study in our laboratory indicated that S179DPRL led
to an increase in vitamin D receptor (VDR) expression in human
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prostate and mouse mammary cells. The VDR in turn interacted
with the p21 promoter leading to an elevation of p21 [26,37,38].
However, as we now show, removal of the BRCA1 response element,
while keeping the VDR response element, eliminated the re-
sponse to S179DPRL. Thus, while the VDR is important, BRCA1 is
essential.
In osteosarcoma cells, we have previously shown that prolac-
tin blocks nuclear translocation of the VDR through the promotion
of formation of a complex between the VDR and BRCA1 [39]. Given
that prolactin also increases the level of BRCA1, whether or not for-
mation of a complex with the VDR would contribute to the effect
of prolactin on BRCA1 function in any cell line would depend on
the relative expression levels of BRCA1 and the VDR.
By contrast to the VDR–BRCA1 complex, formation of a complex
between p-Stat5 and BRCA1 does not affect nuclear translocation
of BRCA1. Instead, the transactivation function of BRCA1 was hin-
dered. Since there is no Stat5 binding motif within the 2400 bp p21
promoter, and removal of the BRCA1 response element eliminates
the response, binding of the BRCA1–p-Stat5 complex to the p21 pro-
moter likely occurs through BRCA1 (Fig. 9).
While both forms of the PRLR transduce a signal leading to in-
creased BRCA1 levels, only the LFPRLR activates Stat5 [33]. Thus
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increased expression of the LFPRLR increases the ability of prolac-
tin to activate Stat5, which would in turn decrease the ability of
BRCA1 to transactivate p21, thereby allowing increased cell prolif-
eration in response to prolactin. The crucial nature of activated Stat5
in this process was demonstrated by the use of the dominant neg-
ative Stat5.
In addition to endocrine and autocrine prolactin, Stat5 signal-
ing is initiated by other ligands that may contribute to prolonged
activation during tumor development. IL-2, for example, is one of
ﬁve cytokines overexpressed in breast cancer, but not detected in
normal mammary tissues [40]. Both IL-2 and the IL-2R have been
detected in malignant breast tumors, and cell proliferation is in-
creased by exogenous IL-2 [41]. In prostate cancers, expression of
the IL-2R is also upregulated compared to normal tissue [42].
Autocrine and endocrine growth hormones have also been impli-
cated in the development and progression of a variety of cancers
[43] and expression of the growth hormone receptor is upregulated
in cancers [44,45]. Stat 5 activation by any one or all of these
hormones/cytokines may contribute to inhibition of BRCA1’s p21-
related activities.
At the same time, each of the Stat5-activating ligands tested in-
creased total BRCA1 levels. Given the correlation between BRCA1
levels and chemoresistance in tumors with wild type BRCA1 [12]
and the ability of both prolactin and growth hormone to increase
chemoresistance [46], it does not seem likely that the formation of
a complex between BRCA1 and p-Stat5 has any inhibitory effect on
DNA repair, although this remains to be directly examined. If Stat5
activation is important to chemoresistance and S179DPRL inhibits
Stat5 activation, then S179DPRL could potentially inhibit DNA repair.
Treatment of cancer cells with other prolactin antagonists has cer-
tainly made themmore susceptible to chemotherapeutics [47] and
S179DPRL alone induces apoptosis ([25], and data herein). However,
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without experimentation, the balance of a variety of reported effects
is diﬃcult to predict. This is because S179DPRL elevates p21 and
p21 in turn has been shown to play several different roles in DNA
repair. Thus, cells expressing mutant p21 are deﬁcient in nucleo-
tide excision repair [48]. Furthermore, p21 is recruited and co-
localized to sites of DNA damage with other repair factors upon
irradiation, suggesting a role in double strand repair [49]. On the
other hand, p21 inhibits the activity of PARP-1 in base excision repair
[50].
Prolactin is produced in several modiﬁed forms [51], one of which,
the phosphorylated form, is able to block the activation of Stat5 sig-
naling [22,52]. In this study, we used the selective PRLR modulator,
S179DPRL, which is a mimic of the phosphorylated hormone
[22,29,33]. It blocks Stat5 signaling, and treatment with either
S179DPRL or a dominant negative form of Stat5 led to an eleva-
tion of p21 in the presence of autocrine or exogenous prolactin. This
is consistent with previously described opposite roles for unmodi-
ﬁed and phosphorylated prolactin in the development of cancer
[20,25–27,33].
Most importantly, the results presented here explain deﬁcient
anti-proliferative BRCA1 functioning in tumor cells expressing wild
type BRCA1. While the pathway we have uncovered would be im-
portant to allow for physiological proliferation in response to
prolactin, prolongation of the prolactin stimulus may lead to excess
proliferation and/or the reduced ability to undergo apoptosis, and
hence to tumor development.
We conclude that prolactin and other hormones/cytokines that
activate Stat5 can have a major impact on tumor development by
interfering with the cell cycle regulatory function of wild type BRCA1.
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